Abstract
Gastric cancer (GC) is one of the most common malignancies of the digestive system with few genetic markers for its early detection and prevention. In this study, differentially expressed genes (DEGs) were analyzed using GEO2R from GSE54129 and GSE13911 of the Gene Expression Omnibus (GEO). Then, gene enrichment analysis, protein-protein interaction (PPI) network construction, and topological analysis were performed on the DEGs by the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, STRING, and Cytoscape. Finally, we performed survival analysis of key genes through the Kaplan-Meier plotter. A total of 1034 DEGs were identified in GC. GO and KEGG results showed that DEGs mainly enriched in plasma membrane, cell adhesion, and PI3K-Akt signaling pathway. Subsequently, the PPI network with 44 nodes and 333 edges was constructed, and 18 candidate genes in the network were focused on by centrality analysis and module analysis. Furthermore, data showed that high expressions of fibronectin 1(FN1), the tissue inhibitor of metalloproteinases 1 (TIMP1), secreted phosphoprotein 1 (SPP1), apolipoprotein E (APOE), and versican (VCAN) were related to poor overall survivals in GC patients. In summary, this study suggests that FN1, TIMP1, SPP1, APOE, and VCAN may act as the key genes in GC.
Highlights
Gastric cancer (GC) is one of the malignant tumors threatening human health, and it is the fifth most common cancer and the third leading cause of cancer death in the world [1, 2]
Two gene expression profiles GSE54129 and GSE13911 were downloaded from the Gene Expression Omnibus (GEO)
The criteria for both gene expression profiles were (a) the samples included two groups of GC tumors and normal tissues; (b) the sample size of each gene expression profile was greater than 60; (c) they were recently updated in the last two years (2019-2020); and (d) they were derived from the same platform: GPL570 [hg-u133_plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Summary
Gastric cancer (GC) is one of the malignant tumors threatening human health, and it is the fifth most common cancer and the third leading cause of cancer death in the world [1, 2]. The cause of the onset of it includes diet, lifestyle, genetic, and infection of helicobacter pylori[3,4,5]. The treatment of gastric cancer includes surgery [6], radiotherapy [7], neoadjuvant chemotherapy [8], and immunotherapy [9]. The survival rate for early gastric cancer patients can reach 90%. It is difficult to detect and diagnose the disease during the early period, resulting in a significant decrease in survival after diagnosis [10].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
